Bioxytran, Inc.
BIXT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.10 | 0.47 | -4.35 |
| FCF Yield | -0.67% | -4.07% | -3.33% | -4.08% |
| EV / EBITDA | -6.09 | -5.77 | -26.77 | 0.00 |
| Quality | ||||
| ROIC | 318.55% | 323.78% | 189.27% | 406.79% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.02 | 0.17 | 0.68 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 89.76% | 55.40% | -5.97% | -56.39% |
| Safety | ||||
| Net Debt / EBITDA | -0.49 | -0.50 | -0.88 | 0.00 |
| Interest Coverage | -2.89 | -7.05 | -4.11 | -13.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -16.57 | -73.04 | -99.16 | 0.00 |